Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv